Teclistamab in relapsed or refractory AL amyloidosis, a multinational retrospective case series

Nathalie Forgeard; Dikelele Elessa; Alexander Carpinteiro; Karim Belhadj; Monique C Minnema; Murielle Roussel; Antoine Huart; Vincent Javaugue; Laurent Pascal; Bruno Royer; Alexis Talbot; Romain Gounot; Ute Hegenbart; Stefan Schonland; Lionel Karlin; Stephanie Harel; Efstathios Kastritis; Frank Bridoux; Arnaud Jaccard; Bertrand Arnulf

doi:10.1182/blood.2023022937

Teclistamab in relapsed or refractory AL amyloidosis, a multinational retrospective case series

Nathalie Forgeard, Dikelele Elessa, Alexander Carpinteiro, Karim Belhadj, Monique C Minnema, Murielle Roussel, Antoine Huart, Vincent Javaugue, Laurent Pascal, Bruno Royer, Alexis Talbot, Romain Gounot, Ute Hegenbart, Stefan Schonland, Lionel Karlin, Stephanie Harel, Efstathios Kastritis, Frank Bridoux, Arnaud Jaccard, Bertrand Arnulf

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Teclistamab shows promising results in R/R AL amyloidosis, with VGPR or better in 88% of patients and involved FLC < 10 mg/L in 76%. We observed a 35% rate of severe infections and no cardiac or kidney related events.

Original language	English
Pages (from-to)	734-737
Number of pages	4
Journal	Blood
Volume	143
Issue number	8
Early online date	14 Dec 2023
DOIs	https://doi.org/10.1182/blood.2023022937
Publication status	Published - 22 Feb 2024

Access to Document

10.1182/blood.2023022937

Cite this

Forgeard, N., Elessa, D., Carpinteiro, A., Belhadj, K., Minnema, M. C., Roussel, M., Huart, A., Javaugue, V., Pascal, L., Royer, B., Talbot, A., Gounot, R., Hegenbart, U., Schonland, S., Karlin, L., Harel, S., Kastritis, E., Bridoux, F., Jaccard, A., & Arnulf, B. (2024). Teclistamab in relapsed or refractory AL amyloidosis, a multinational retrospective case series. Blood, 143(8), 734-737. https://doi.org/10.1182/blood.2023022937

@article{9da23cc22dd8427f938f34985885e045,

title = "Teclistamab in relapsed or refractory AL amyloidosis, a multinational retrospective case series",

abstract = "Teclistamab shows promising results in R/R AL amyloidosis, with VGPR or better in 88% of patients and involved FLC < 10 mg/L in 76%. We observed a 35% rate of severe infections and no cardiac or kidney related events.",

author = "Nathalie Forgeard and Dikelele Elessa and Alexander Carpinteiro and Karim Belhadj and Minnema, {Monique C} and Murielle Roussel and Antoine Huart and Vincent Javaugue and Laurent Pascal and Bruno Royer and Alexis Talbot and Romain Gounot and Ute Hegenbart and Stefan Schonland and Lionel Karlin and Stephanie Harel and Efstathios Kastritis and Frank Bridoux and Arnaud Jaccard and Bertrand Arnulf",

note = "Copyright {\textcopyright} 2023 American Society of Hematology.",

year = "2024",

month = feb,

day = "22",

doi = "10.1182/blood.2023022937",

language = "English",

volume = "143",

pages = "734--737",

journal = "Blood",

issn = "0006-4971",

publisher = "Elsevier",

number = "8",

}

Forgeard, N, Elessa, D, Carpinteiro, A, Belhadj, K, Minnema, MC, Roussel, M, Huart, A, Javaugue, V, Pascal, L, Royer, B, Talbot, A, Gounot, R, Hegenbart, U, Schonland, S, Karlin, L, Harel, S, Kastritis, E, Bridoux, F, Jaccard, A & Arnulf, B 2024, 'Teclistamab in relapsed or refractory AL amyloidosis, a multinational retrospective case series', Blood, vol. 143, no. 8, pp. 734-737. https://doi.org/10.1182/blood.2023022937

TY - JOUR

T1 - Teclistamab in relapsed or refractory AL amyloidosis, a multinational retrospective case series

AU - Forgeard, Nathalie

AU - Elessa, Dikelele

AU - Carpinteiro, Alexander

AU - Belhadj, Karim

AU - Minnema, Monique C

AU - Roussel, Murielle

AU - Huart, Antoine

AU - Javaugue, Vincent

AU - Pascal, Laurent

AU - Royer, Bruno

AU - Talbot, Alexis

AU - Gounot, Romain

AU - Hegenbart, Ute

AU - Schonland, Stefan

AU - Karlin, Lionel

AU - Harel, Stephanie

AU - Kastritis, Efstathios

AU - Bridoux, Frank

AU - Jaccard, Arnaud

AU - Arnulf, Bertrand

PY - 2024/2/22

Y1 - 2024/2/22

N2 - Teclistamab shows promising results in R/R AL amyloidosis, with VGPR or better in 88% of patients and involved FLC < 10 mg/L in 76%. We observed a 35% rate of severe infections and no cardiac or kidney related events.

AB - Teclistamab shows promising results in R/R AL amyloidosis, with VGPR or better in 88% of patients and involved FLC < 10 mg/L in 76%. We observed a 35% rate of severe infections and no cardiac or kidney related events.

UR - http://www.scopus.com/inward/record.url?scp=85185184874&partnerID=8YFLogxK

U2 - 10.1182/blood.2023022937

DO - 10.1182/blood.2023022937

M3 - Article

C2 - 38096365

SN - 0006-4971

VL - 143

SP - 734

EP - 737

JO - Blood

JF - Blood

IS - 8

ER -

Teclistamab in relapsed or refractory AL amyloidosis, a multinational retrospective case series

Abstract

Access to Document

Other files and links

Fingerprint

Cite this